Government Starts Third Dose Booster Vaccination Program in January 2022
PALANGKA RAYA – EXECUTIVE ADMINISTRATION BUREAU. The Central Kalimantan Covid-19 Handling Task Force delivered a Press Release on the progress of handling the Covid-19 pandemic in Central Kalimantan until 15.00 p.m., Thursday (6/1/2022). The Central Kalimantan Covid-19 Task Force Team, as well as the Central Covid-19 Handling Task Force, said that the government plans to implement the third dose booster vaccination program on January 12, 2022.
Spokesperson for the Covid-19 Task Force, Prof. Wiku Adisasmito said that so far the clinical trials of giving booster vaccines have been carried out and no severe symptoms of Adverse Events Following Immunization (AEFI) have been found.
This third dose will first be given to people over the age of 18 years. For the recommended injection, the range between the second and third dose injection is at least 6 months. This program is prioritized for regencies/municipality whose vaccination achievement has reached 70% for the first dose and 60% for the second dose. As is known, there are at least 21 million people targeted for the booster vaccination program in January 2022. As of January 3, 2022, the government has secured 113 million doses of booster vaccine stock. This third dose booster vaccination program is also in line with the World Health Organization’s (WHO) target in the first trimester of 2022. This program will start after the official recommendation is issued from the Indonesian Technical Advisory Group on Immunization (ITAGI) and the Food and Drug Administration (BPOM), including the type of vaccine to be used.
Furthermore, based on Instruction of the Minister of Home Affairs Number 02 of 2022 dated January 3, 2022 on the Enforcement of Restrictions on Community Activities (PPKM) Level 3, Level 2, and Level 1 and Optimizing the Corona Virus Disease 2019 Handling Command Post at the Village and District Levels to Control the Spread of Corona Virus Disease 2019 in Sumatra, Nusa Tenggara, Kalimantan, Sulawesi, Maluku, and Papua, for regencies/municipality in Central Kalimantan Province, there are three criteria, namely Level 1, Level 2, and Level 3 (valid until January 17, 2022). The regencies/municipality with these criteria include:• Level 1, covering East Kotawaringin, Kapuas, South Barito, North Barito, Seruyan, Lamandau, Gunung Mas, Pulang Pisau, and East Barito.• Level 2, covering West Kotawaringin, Katingan, Murung Raya, and Palangka Raya.• Level 3, covering Sukamara.
The following is the number of accumulated data on positive confirmed Covid-19 patients in Central Kalimantan, where there was an addition of 1 person, bringing the total to 46723 people. There was an addition of 1 person recovered, bringing the total to 45122 people. And there was no addition of death case, so the total remained 1588 people.
The data of Covid-19 that has been accumulated is as follows: 1 person added for Confirmation Cases, namely in Katingan, from 46722 people to 46723 people. There was an addition of 1 person recovered, namely in Palangka Raya, from 45121 people to 45122 people. There was no addition of patient under treatment, so there were still 13 people. There were no additional cases of death, so there were still 1588 people, with a mortality rate (CFR) of 3.4%.
For Bed Occupancy Rate in Hospitals (BOR), Intensive Beds experienced a decrease in Bed Occupancy (4.76%), from 14.29 to 9.52%, in which no Regency/Municipality had a BOR above 50%. Meanwhile, Isolated Beds experienced an increase in Bed Occupancy (0.38%), from 0.91% to 1.28%, in which no Regency/Municipality had a BOR above 50%.
For the achievement of vaccination target of 2,036,104, the realization of Dose I Vaccination for Central Kalimantan Province has reached 80.65%. The regency that has not yet reached 70% is Gunung Mas (68.77%). For the achievement of vaccination target for teachers and education personnel, high schools (SMA), and equivalent vocational schools (SMK), the realization of PNS/GTT/PTT Vaccination do not increase so that it remained at 6,258 or 79.01%. The first dose of SMA/SMK did not have any change, so it remained at 73.202 or 76.95%, and the second dose of SMA/SMK did not have any change either, so it remained at 32,403 or 34.06%. (din/trans.by feb)